PubRank

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Clinical Trial ID NCT00769704

PubWeight™ 33.88‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00769704

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol 2015 4.85
2 Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011 2.89
3 New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol 2013 1.72
4 The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment. Clin Cancer Res 2015 1.52
5 Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology 2013 1.36
6 Trial Watch:: Oncolytic viruses for cancer therapy. Oncoimmunology 2014 1.22
7 Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. P T 2012 1.19
8 Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2015 1.06
9 Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress. Curr Pharm Biotechnol 2012 1.03
10 Live viruses to treat cancer. J R Soc Med 2013 0.89
11 First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology 2015 0.88
12 Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses. Mol Ther Methods Clin Dev 2016 0.86
13 Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci 2016 0.86
14 Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade. Viruses 2016 0.85
15 Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy 2015 0.83
16 Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology 2015 0.83
17 Cancer immunotherapy turns viral. Oncoimmunology 2013 0.82
18 Immunovirotherapy for the treatment of glioblastoma. Oncoimmunology 2014 0.82
19 Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1. Front Oncol 2014 0.82
20 Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm. J Exp Clin Cancer Res 2014 0.80
21 Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma. Adv Ther 2016 0.80
22 Biomarkers as key contributors in treating malignant melanoma metastases. Dermatol Res Pract 2011 0.79
23 Stock market returns and clinical trial results of investigational compounds: an event study analysis of large biopharmaceutical companies. PLoS One 2013 0.78
24 Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges. Semin Oncol 2015 0.77
25 Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"? Mol Ther Oncolytics 2015 0.77
26 A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial. J Immunother Cancer 2015 0.76
27 New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015 0.76
28 First-in-class small molecule potentiators of cancer virotherapy. Sci Rep 2016 0.76
29 Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. Head Neck 2016 0.76
30 Immunovirotherapy for glioblastoma. Cell Cycle 2013 0.75
31 Immunotherapy in the management of melanoma: current status. Immunotargets Ther 2013 0.75
32 Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. Onco Targets Ther 2016 0.75
Next 100